About Interpace Biosciences
Interpace Biosciences is a company based in Parsippany Troy Hills (United States) founded in 1986. The company has 94 employees as of February 28, 2023. Interpace Biosciences offers products and services including PancraGEN, ThyGeNEXT, and ThyraMIR. Interpace Biosciences operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Parsippany Troy Hills, United States
- Employees 94 as on 28 Feb, 2023
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Interpace Biosciences, Inc.
-
Annual Revenue
$46.93 M (USD)17as on Dec 31, 2024
-
Net Profit
$6.7 M (USD)0as on Dec 31, 2024
-
EBITDA
$8.11 M (USD)105as on Dec 31, 2024
-
Latest Funding Round
$47 M (USD), Post-IPO
Oct 11, 2024
-
Investors
1315 Capital
& 1 more
-
Employee Count
94
as on Feb 28, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Interpace Biosciences
Interpace Biosciences offers a comprehensive portfolio of products and services, including PancraGEN, ThyGeNEXT, and ThyraMIR.
Assesses risk of pancreatic cyst cancer for early detection.
Evaluates thyroid nodules to guide treatment decisions.
Complements thyroid testing for improved accuracy in diagnostics.
People of Interpace Biosciences
Unlock access to complete
Funding Insights of Interpace Biosciences
Investors in Interpace Biosciences
Interpace Biosciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include 1315 Capital and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Expansion and growth capital is provided by 1315 Capital to healthcare companies.
|
Locked | Locked | Locked | |
|
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
|
Locked | Locked | Locked |
Investor details for Interpace Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Interpace Biosciences
Investment portfolio details for Interpace Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Interpace Biosciences
Detailed financials for Interpace Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Interpace Biosciences Comparisons
Peer comparison for Interpace Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Interpace Biosciences
Interpace Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Interpace Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Interpace Biosciences
Complete news archive for Interpace Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Interpace Biosciences
Interpace Biosciences was founded in 1986 and raised its 1st funding round 31 years after it was founded.
Interpace Biosciences is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany Troy Hills, New Jersey, United States.
Thomas Burnell is the current CEO of Interpace Biosciences.
As of Feb 28, 2023, the latest employee count at Interpace Biosciences is 94.
Annual revenue of Interpace Biosciences is $46.93M as on Dec 31, 2024.
Founded in 1986 and headquartered in Parsippany Troy Hills, United States, operations in the healthcare sector are focused on molecular diagnostics for cancer. Evidence-based tests for early detection and treatment guidance are offered, along with pathology services. These solutions support clinical decision-making in oncology, with services delivered through a network addressing gastrointestinal, thyroid, and pancreatic cancers.
Interpace Biosciences's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Interpace Biosciences offers PancraGEN, ThyGeNEXT, and ThyraMIR.
Interpace Biosciences has 2 investors. Key investors include 1315 Capital, and Ampersand Capital Partners.